Genetic factors affecting treatment response in acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research investigates how specific genetic variations influence the side effects and treatment outcomes for patients with newly diagnosed acute myeloid leukemia (AML) receiving azacitidine and venetoclax. It is a prospective pilot study that will collect buccal swabs for genetic analysis and measure venetoclax levels during treatment. The study aims to identify associations between genetic markers and the toxicity or efficacy of the treatment regimen. Participants will be recruited from designated cancer centers in North Carolina.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years of age at the time of consent
* Confirmed diagnosis of AML
* Planned initial treatment with azacitidine and venetoclax
* Ability to read and understand the English and/or Spanish language
* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

* None

Where it's running

• Levine Cancer Institute
  Charlotte, North Carolina, United States Recruiting
• Wake Forest Baptist Comprehensive Cancer Center
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Brittany Ragon, MD — Atrium Health Wake Forest Baptist Comprehensive Cancer Center
• Study coordinator: Courtney Schepel
• Email: courtney.schepel@advocatehealth.org
• Phone: (980) 292-0817

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Bleximenib added to venetoclax and azacitidine for newly diagnosed NPM1- or KMT2A-mutated AML

  This trial will test whether adding bleximenib to venetoclax plus azacitidine helps people with newly diagnosed AML that has NPM1 or KMT2A mutations who cannot have intensive chemotherapy.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 269 other locations · NCT06852222

• Genetic analysis in women with metastatic ovarian cancer during PARP inhibitor treatment

  This study is testing how PARP inhibitor treatment affects the genes and blood cells of women with metastatic ovarian cancer to see if it leads to any serious side effects.

  Recruiting European Institute of Oncology · Milan · NCT06785077

• Combining Venetoclax with Intensive Therapy for Acute Myeloid Leukemia Patients

  This study is testing if adding a drug called Venetoclax to standard chemotherapy can help newly diagnosed acute myeloid leukemia patients who aren't responding well to their initial treatment.

  Recruiting Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT06643962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.